Tandem Capital Management Corp ADV Increases Stock Position in Danaher Corporation $DHR

Tandem Capital Management Corp ADV raised its holdings in Danaher Corporation (NYSE:DHR) by 0.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,807 shares of the conglomerate’s stock after purchasing an additional 65 shares during the quarter. Danaher accounts for about 1.5% of Tandem Capital Management Corp ADV’s holdings, making the stock its 24th biggest position. Tandem Capital Management Corp ADV’s holdings in Danaher were worth $2,925,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in DHR. Hills Bank & Trust Co lifted its position in Danaher by 0.3% during the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate’s stock worth $3,693,000 after acquiring an additional 53 shares during the last quarter. Worth Financial Advisory Group LLC increased its holdings in shares of Danaher by 4.6% during the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock worth $236,000 after purchasing an additional 53 shares during the period. Sageworth Trust Co increased its holdings in shares of Danaher by 2.3% during the 1st quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate’s stock worth $493,000 after purchasing an additional 54 shares during the period. 1834 Investment Advisors Co. increased its holdings in shares of Danaher by 3.3% during the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 54 shares during the period. Finally, Bruce G. Allen Investments LLC increased its holdings in shares of Danaher by 13.1% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock worth $92,000 after purchasing an additional 54 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 1.7%

Danaher stock opened at $205.13 on Thursday. The company has a market cap of $146.88 billion, a P/E ratio of 43.64, a price-to-earnings-growth ratio of 2.97 and a beta of 0.77. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.41. The company has a fifty day simple moving average of $200.41 and a 200 day simple moving average of $197.38. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to analysts’ expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is currently 27.23%.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on DHR. Barclays reissued an “overweight” rating and issued a $225.00 target price (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research report on Friday, June 27th. Guggenheim restated a “buy” rating and issued a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Rothschild & Co Redburn reiterated a “neutral” rating and set a $220.00 target price (down from $245.00) on shares of Danaher in a research report on Wednesday. Finally, Evercore ISI increased their price objective on shares of Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a report on Tuesday. Seventeen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $244.60.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.